Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of a placebo-controlled trial of remdesivir in COVID-19 patients have been published in the Lancet.

In early February scientists in China, supported by the ISARIC Support Centre at the University of Oxford, launched a placebo-controlled randomised trial of remdesivir in patients hospitalised with COVID-19.

The results, published today in the Lancet, found no significant clinical benefit from use of the drug. However, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir within 10 days after illness onset, compared to standard care.

One hundred and fifty-eight patients were randomised to remdesivr and 79 patients were randomised to placebo for 14 days. The trial had to be stopped early due to lack of patients, which meant the trial was underpowered and the results are inconclusive.

Professor Peter Horby, a co-investigator on the trial, said: 'It is an outstanding achievement of Dr Cao Bin and his team to have completed a gold-standard clinical trial in the very early days of a major emergency. It is disappointing that we did not see a clear benefit from remdesivir. However, there were suggestions of a possible benefit, particularly in those treated earlier. Ongoing, bigger trials will confirm or refute these findings.'

Read the full story on the University of Oxford website

Similar stories

African trial of novel HIV vaccine candidate starts

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.

Reducing fat in the diabetic heart could improve recovery from heart attack

New research from the Department of Physiology, Anatomy and Genetics has shown that in type 2 diabetes an overload of lipids reduces the heart’s ability to generate energy during a heart attack, decreasing chances of recovery.

Brain cortex may regulate the need for sleep

Why we sleep, and the processes behind sleep, are amongst the most interesting questions in modern neuroscience.

New data show rise in hospital admissions for unvaccinated pregnant women

The Chief Midwifery Officer for England will urge expectant mums to have their COVID-19 vaccination as soon as possible. This follows a worrying rise in unvaccinated women being admitted to hospital with severe COVID-19, and evidence that the Delta variant poses a significantly greater risk than all previous strains.

Cooking with coal or wood associated with increased risk of major eye diseases

A study involving nearly half a million people in China reveals a clear link between cooking with wood or coal, and an increased risk of major eye diseases that can lead to blindness, according to a report published today in PLOS Medicine.

The mental health impacts of being an Olympian

Dr David M. Lyreskog, Postdoctoral Researcher, Department of Psychiatry explores the topic in detail.